Compugen (CGEN) EBT Margin (2009 - 2026)

Compugen recorded quarterly EBT Margin of 352.21% in Q1 2026, up 12.51% quarter-over-quarter from 313.05% in Q1 2025, and up 3916.0% year-over-year from 8.77% in Q1 2025.

Compugen's EBT Margin history runs 2 years deep, the most recent figure standing at 352.21% for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -6.40%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 41.95%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 23.05%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 18.99%
10 Compugen 234.03 Mn 142.28 Mn 352,000.00 352.21%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 352.21%
Dec 31, 2025 84.42%
Sep 30, 2025 -366.95%
Jun 30, 2025 -1,723.07%
Mar 31, 2025 313.05%
Dec 31, 2024 -415.57%
Sep 30, 2024 33.74%
Jun 30, 2024 -248.28%
Mar 31, 2024 283.86%
Dec 31, 2023 55.95%
Dec 31, 2022 -40.45%
Dec 31, 2020 -428.15%
Sep 30, 2018 -39.88%
Dec 31, 2016 -16,022.64%
Sep 30, 2016 -11,115.71%
Jun 30, 2016 -1,333.06%
Mar 31, 2016 -9,538.71%
Dec 31, 2015 -0.99%
Sep 30, 2015 -2,944.10%
Jun 30, 2015 -3,052.91%
Mar 31, 2015 -1,197.47%
Dec 31, 2014 -18.04%
Sep 30, 2014 -314.03%
Jun 30, 2014 -115.02%
Mar 31, 2014 -88.98%
Dec 31, 2013 -145.52%
Sep 30, 2013 -288.49%
Jun 30, 2013 -13,813.64%
Mar 31, 2013 -2,082.72%
Dec 31, 2012 -4,009.70%
Sep 30, 2012 -3,250.00%
Dec 31, 2010 -1,210.53%
Jun 30, 2010 -122.25%
Mar 31, 2010 -2,174.40%
Dec 31, 2009 -7,804.00%
Sep 30, 2009 2,446.88%